Logo image of ALNOX.PA

NOXXON PHARMA NV (ALNOX.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:ALNOX - NL0012044762 - Common Stock

0.041 EUR
-0.01 (-18%)
Last: 7/18/2022, 7:00:00 PM

ALNOX.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap3.05M
Revenue(TTM)N/A
Net Income(TTM)-14.45M
Shares74.51M
Float0
52 Week High0.41
52 Week Low0.04
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.22
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO2018-09-10
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
ALNOX.PA short term performance overview.The bars show the price performance of ALNOX.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

ALNOX.PA long term performance overview.The bars show the price performance of ALNOX.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALNOX.PA is 0.041 EUR. In the past month the price decreased by -38.99%. In the past year, price decreased by -88.28%.

NOXXON PHARMA NV / ALNOX Daily stock chart

ALNOX.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALNOX.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALNOX.PA. ALNOX.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALNOX.PA Financial Highlights

Over the last trailing twelve months ALNOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 40.04% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -147.9%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1.23%
Sales Q2Q%N/A
EPS 1Y (TTM)40.04%
Revenue 1Y (TTM)N/A

ALNOX.PA Forecast & Estimates

10 analysts have analysed ALNOX.PA and the average price target is 7.39 EUR. This implies a price increase of 17919.93% is expected in the next year compared to the current price of 0.041.


Analysts
Analysts84
Price Target7.39 (17924.39%)
EPS Next Y-19.23%
Revenue Next YearN/A

ALNOX.PA Ownership

Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

ALNOX.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ARGX.BR ARGENX SE 62.93 41.67B
1AE.DE ARGENX SE 64.86 42.73B
22UA.DE BIONTECH SE-ADR N/A 22.31B
2X1.DE ABIVAX SA N/A 8.03B
ABVX.PA ABIVAX SA N/A 7.97B
GXE.DE GALAPAGOS NV N/A 1.92B
GLPG.AS GALAPAGOS NV N/A 1.81B
IVA.PA INVENTIVA SA N/A 1.03B
6IV.DE INVENTIVA SA N/A 967.31M
NANO.PA NANOBIOTIX N/A 873.66M
PHIL.MI PHILOGEN SPA 18.95 631.58M
FYB.DE FORMYCON AG N/A 409.50M

Related stock screener links

About ALNOX.PA

Company Profile

ALNOX logo image NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.

Company Info

NOXXON PHARMA NV

Max-Dohrn-Str. 8-10

Berlin BERLIN DE

Employees: 13

ALNOX Company Website

Phone: 49307262470.0

NOXXON PHARMA NV / ALNOX.PA FAQ

Can you describe the business of NOXXON PHARMA NV?

NOXXON Pharma NV operates as a clinical-stage biopharmaceutical company, which focuses on cancer treatment. The company is headquartered in Berlin, Berlin and currently employs 13 full-time employees. The company went IPO on 2018-09-10. The firm's main product is the Spiegelmer platform. Spiegelmers are a variant of a drug class called aptamers, which are based on deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and are built on a backbone of mirror-image RNA or DNA - L-stereoisomers. The firm's lead candidate, NOX-A12, is under development as a combination therapy for a number of cancer indications using immuno-oncology approaches, such as immune checkpoint inhibition and current standards of care, such as chemotherapy and radiotherapy. The firm also develops NOX-E36, which is aimed at the treatment of complications arising from diabetic nephropathy.


What is the current price of ALNOX stock?

The current stock price of ALNOX.PA is 0.041 EUR. The price decreased by -18% in the last trading session.


Does NOXXON PHARMA NV pay dividends?

ALNOX.PA does not pay a dividend.


How is the ChartMill rating for NOXXON PHARMA NV?

ALNOX.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the GICS sector and industry of ALNOX stock?

NOXXON PHARMA NV (ALNOX.PA) operates in the Health Care sector and the Biotechnology industry.


What is the market capitalization of ALNOX stock?

NOXXON PHARMA NV (ALNOX.PA) has a market capitalization of 3.05M EUR. This makes ALNOX.PA a Nano Cap stock.